The role of dolutegravir in the management of HIV infection

The role of dolutegravir in the management of HIV infection

Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid. It is hepatically metabolized...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infection and drug resistance 2015-01, Vol.8, p.19-29
Hauptverfasser: Miller, Misty M, Liedtke, Michelle D, Lockhart, Staci M, Rathbun, R Chris
Format: Artikel
Sprache:eng
Schlagworte:
Drug therapy
HIV infection
Review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 29
container_issue
container_start_page 19
container_title Infection and drug resistance
container_volume 8
creator Miller, Misty M
Liedtke, Michelle D
Lockhart, Staci M
Rathbun, R Chris
description Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid. It is hepatically metabolized by uridine diphosphate glucuronosyl transferase 1A1; no inhibition or induction of cytochrome P450 enzymes is noted. As a substrate of CYP 3A4, dolutegravir is affected by rifampin, efavirenz, tipranavir/ritonavir, fosamprenavir/ritonavir, and dose increase is required. Dolutegravir inhibits the organic cation transporter 2, resulting in decreased creatinine clearance with no apparent decrease in renal function. Other adverse effects are minimal but include diarrhea, headache, and nausea. Clinical trials in treatment-naïve and experienced patients are ongoing and will be presented in this text.
doi_str_mv 10.2147/IDR.S58706
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4340460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A445875542</galeid><sourcerecordid>A445875542</sourcerecordid><originalsourceid>FETCH-LOGICAL-g364t-d5584580c8c8b4c5e0112887dde9b7ee7cc372fbf199549473e54e53db5b068d3</originalsourceid><addsrcrecordid>eNptkVlLxDAUhYMoKjov_gApCOJLx6RZiyAM4zYwILi9hjS9bSNto10E_70ZXJgBk4dccr57yLlB6IjgaUKYPF9cPUwfuZJYbKF9QqSKRSrp9lq9hyZ9_4rDoqlgMtlFewmXlKZE7qOLpwqiztcQ-SLKfT0OUHbmw3WRa6MhaI1pTQkNtMOKuFu8BKEAOzjfHqKdwtQ9TH7OA_R8c_00v4uX97eL-WwZl1SwIc45V4wrbJVVGbMcMCGJUjLPIc0kgLSWyqTICpKmnKVMUuAMOM0znmGhcnqALr9938asgdyGt3Sm1m-da0z3qb1xelNpXaVL_6EZZZgJHAzOfgw6_z5CP-jG9Rbq2rTgx14TIbDgRDAR0JNvtDQ16BDVB0e7wvWMhRSSc5YEavoPFXYOjbO-hcKF-42G07WGCkw9VP1q2mGM_SZ4vJ71L-Tvj9Ev-V2VVA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660651646</pqid></control><display><type>article</type><title>The role of dolutegravir in the management of HIV infection</title><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Taylor &amp; Francis Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Miller, Misty M ; Liedtke, Michelle D ; Lockhart, Staci M ; Rathbun, R Chris</creator><creatorcontrib>Miller, Misty M ; Liedtke, Michelle D ; Lockhart, Staci M ; Rathbun, R Chris</creatorcontrib><description>Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid. It is hepatically metabolized by uridine diphosphate glucuronosyl transferase 1A1; no inhibition or induction of cytochrome P450 enzymes is noted. As a substrate of CYP 3A4, dolutegravir is affected by rifampin, efavirenz, tipranavir/ritonavir, fosamprenavir/ritonavir, and dose increase is required. Dolutegravir inhibits the organic cation transporter 2, resulting in decreased creatinine clearance with no apparent decrease in renal function. Other adverse effects are minimal but include diarrhea, headache, and nausea. Clinical trials in treatment-naïve and experienced patients are ongoing and will be presented in this text.</description><identifier>ISSN: 1178-6973</identifier><identifier>EISSN: 1178-6973</identifier><identifier>DOI: 10.2147/IDR.S58706</identifier><identifier>PMID: 25733917</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Drug therapy ; HIV infection ; Review</subject><ispartof>Infection and drug resistance, 2015-01, Vol.8, p.19-29</ispartof><rights>COPYRIGHT 2015 Dove Medical Press Limited</rights><rights>2015 Miller et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340460/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340460/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25733917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, Misty M</creatorcontrib><creatorcontrib>Liedtke, Michelle D</creatorcontrib><creatorcontrib>Lockhart, Staci M</creatorcontrib><creatorcontrib>Rathbun, R Chris</creatorcontrib><title>The role of dolutegravir in the management of HIV infection</title><title>Infection and drug resistance</title><addtitle>Infect Drug Resist</addtitle><description>Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid. It is hepatically metabolized by uridine diphosphate glucuronosyl transferase 1A1; no inhibition or induction of cytochrome P450 enzymes is noted. As a substrate of CYP 3A4, dolutegravir is affected by rifampin, efavirenz, tipranavir/ritonavir, fosamprenavir/ritonavir, and dose increase is required. Dolutegravir inhibits the organic cation transporter 2, resulting in decreased creatinine clearance with no apparent decrease in renal function. Other adverse effects are minimal but include diarrhea, headache, and nausea. Clinical trials in treatment-naïve and experienced patients are ongoing and will be presented in this text.</description><subject>Drug therapy</subject><subject>HIV infection</subject><subject>Review</subject><issn>1178-6973</issn><issn>1178-6973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNptkVlLxDAUhYMoKjov_gApCOJLx6RZiyAM4zYwILi9hjS9bSNto10E_70ZXJgBk4dccr57yLlB6IjgaUKYPF9cPUwfuZJYbKF9QqSKRSrp9lq9hyZ9_4rDoqlgMtlFewmXlKZE7qOLpwqiztcQ-SLKfT0OUHbmw3WRa6MhaI1pTQkNtMOKuFu8BKEAOzjfHqKdwtQ9TH7OA_R8c_00v4uX97eL-WwZl1SwIc45V4wrbJVVGbMcMCGJUjLPIc0kgLSWyqTICpKmnKVMUuAMOM0znmGhcnqALr9938asgdyGt3Sm1m-da0z3qb1xelNpXaVL_6EZZZgJHAzOfgw6_z5CP-jG9Rbq2rTgx14TIbDgRDAR0JNvtDQ16BDVB0e7wvWMhRSSc5YEavoPFXYOjbO-hcKF-42G07WGCkw9VP1q2mGM_SZ4vJ71L-Tvj9Ev-V2VVA</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Miller, Misty M</creator><creator>Liedtke, Michelle D</creator><creator>Lockhart, Staci M</creator><creator>Rathbun, R Chris</creator><general>Dove Medical Press Limited</general><general>Dove Medical Press</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>The role of dolutegravir in the management of HIV infection</title><author>Miller, Misty M ; Liedtke, Michelle D ; Lockhart, Staci M ; Rathbun, R Chris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g364t-d5584580c8c8b4c5e0112887dde9b7ee7cc372fbf199549473e54e53db5b068d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Drug therapy</topic><topic>HIV infection</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miller, Misty M</creatorcontrib><creatorcontrib>Liedtke, Michelle D</creatorcontrib><creatorcontrib>Lockhart, Staci M</creatorcontrib><creatorcontrib>Rathbun, R Chris</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infection and drug resistance</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, Misty M</au><au>Liedtke, Michelle D</au><au>Lockhart, Staci M</au><au>Rathbun, R Chris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of dolutegravir in the management of HIV infection</atitle><jtitle>Infection and drug resistance</jtitle><addtitle>Infect Drug Resist</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>8</volume><spage>19</spage><epage>29</epage><pages>19-29</pages><issn>1178-6973</issn><eissn>1178-6973</eissn><abstract>Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid. It is hepatically metabolized by uridine diphosphate glucuronosyl transferase 1A1; no inhibition or induction of cytochrome P450 enzymes is noted. As a substrate of CYP 3A4, dolutegravir is affected by rifampin, efavirenz, tipranavir/ritonavir, fosamprenavir/ritonavir, and dose increase is required. Dolutegravir inhibits the organic cation transporter 2, resulting in decreased creatinine clearance with no apparent decrease in renal function. Other adverse effects are minimal but include diarrhea, headache, and nausea. Clinical trials in treatment-naïve and experienced patients are ongoing and will be presented in this text.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>25733917</pmid><doi>10.2147/IDR.S58706</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6973
ispartof Infection and drug resistance, 2015-01, Vol.8, p.19-29
issn 1178-6973
1178-6973
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4340460
source DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; Taylor & Francis Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access
subjects Drug therapy
HIV infection
Review
title The role of dolutegravir in the management of HIV infection
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A39%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20dolutegravir%20in%20the%20management%20of%20HIV%20infection&rft.jtitle=Infection%20and%20drug%20resistance&rft.au=Miller,%20Misty%20M&rft.date=2015-01-01&rft.volume=8&rft.spage=19&rft.epage=29&rft.pages=19-29&rft.issn=1178-6973&rft.eissn=1178-6973&rft_id=info:doi/10.2147/IDR.S58706&rft_dat=%3Cgale_pubme%3EA445875542%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1660651646&rft_id=info:pmid/25733917&rft_galeid=A445875542&rfr_iscdi=true